1
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
MassBiologics-University of MA Medical School is a company with 1 orphan drug designation across 2 rare diseases. 3 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Aicardi-Goutieres syndrome 7 | monoclonal antibody directed at hepatitis C virus E2 glycoprotein | Des.TrialAppr. |
| Gaucher disease | monoclonal antibody directed at hepatitis C virus E2 glycoprotein | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
3
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
3
affecting portfolio